Treatment of relapsed mesothelioma with abemaciclib has resulted in 15% partial responses and 54% stable diseases in a recent phase II clinical trial [NCT03654833] using negative p16 IHC staining as an inclusion criterion [54]. This evidence concerns the gene CDKN2A and mesothelioma.